Drug Index

Pembrolizumab

 
print

Mechanism :

Pembrolizumab is a highly selective anti-PD-1 humanized monoclonal antibody which inhibits programmed cell death-1 (PD-1) activity by binding to the PD-1 receptor on T-cells to block PD-1 ligands (PD-L1 and PD-L2) from binding.


Indication :

• Relapsed or refractory Hodgkin’s lymphoma, primary mediastinal large B-cell lymphoma

• Recurrent or metastatic cervical cancer, gastric cancer, head and neck cancer.

• Unresectable or metastatic melanoma, microsatellite instability-high cancer, urothelial carcinoma.


Contraindications :

Hypersensitivity to pembrolizumab or any component of the formulation.


Dosing :

Relapsed or refractory Hodgkin’s lymphoma, primary mediastinal large B-cell lymphoma; unresectable or metastatic microsatellite instability-high cancer:

≥2 years: 2 mg/kg IV (Maximum: 200 mg) once every 3 weeks until disease progression or unacceptable toxicity. Duration: Up to 24 months.


Adverse Effect :

Peripheral edema, fatigue, headache, pruritus, skin rash, hyperglycemia, hypoalbuminemia, hyponatremia, hypertriglyceridemia, hypophosphatemia, anorexia, nausea, constipation, UTI, anemia, lymphocytosis, thrombocytopenia, increased serum ALP, AST, ALT, creatinine, musculoskeletal pain, cough, dyspnea, fever.


Interaction :

Thalidomide Analogues: Pembrolizumab may enhance the adverse/toxic effect of Thalidomide Analogues.


07/18/2019 12:52:03 Pembrolizumab
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0